ENDRA Life Sciences Inc. NDRA
Set alert
4.75 USD -0.13 -2.66%
At close · Oct 30
4.51 -0.24 -5.05%
After hours · Oct 30, 4:00 PM ET
4.72 Day range 4.86
3.26 52-week range 6.70
- YTD
- +4.86%
- 1 year
- -2.66%
- Open
- 4.85
- Prev close
- 4.88
- Mkt cap
- 7.12M
- Vol
- 10.57K
- Avg vol
- 31.27K
- EPS
- -6.26
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.72
- High
- 4.86
- Forward P/E
- -0.02
- Beta
- 0.74
- Short ratio
- 0.05
- Inst. own
- 0.49%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 6.68
- 200-d avg
- 291.96
- 1y target
- 2,625.00
Key statistics
- Market cap
- 3.01M
- Enterprise value
- -5.66M
- Trailing P/E
- 0.00
- Forward P/E
- -0.02
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.21
- EPS (TTM)
- -105.78
- Beta
- 0.74
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -2.48M
- Total cash
- 6.40M
- Total debt
- 549.13K
- Return on equity
- -120.13%
- Shares outstanding
- 536.91K
- Short % of float
- 4.64%
- 50-day average
- 6.68
- 200-day average
- 291.96
Analyst view
Consensus: none
Price target (mean) 2,625.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -143.50.
Financials — quick view
NDRA Revenue — quarterly 0
NDRA Net income — quarterly 159.94K
NDRA EPS — quarterly 0.12
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 15, 2024 | Sep 1, 2024 | -62.24 | -5.85 | +56.39 | +90.60% |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -139.86 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | -454.55 | — | — |
| Mar 28, 2024 | Dec 1, 2023 | 0.00 | -297.20 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -699.30 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -751.75 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 7, 2024 | Ascendiant Capital | main | Buy | Buy |
| Mar 31, 2023 | HC Wainwright & Co. | reit | — | Buy |
About ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- endrainc.com
News
- ENDRA Life Sciences (NASDAQ:NDRA) Shares Climb 1.9% – Time to Buy?
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- ENDRA Life Sciences Q2 EPS $0.06 Beats $(0.84) Estimate
- ENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
- ASP Isotopes Issues Letter to Shareholders
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- Join the Live Investor Webinar for Noble Africa, the Proposed ASP Isotopes Spin-Out Creating a Public Helium Company
- Join the Live Investor Webinar for Noble Africa, the Proposed ASP Isotopes Spin-Out Creating a Public Helium Company
Your note
Sign in to keep a note on NDRA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BASENESE LOUIS J. | Director | Sale | Aug 25, 2021 | 49,068 |
| DIGIANDOMENICO ANTHONY | Director | Purchase | May 1, 2023 | 102,434 |
| GAMBHIR SANJIV SAM | Director | Stock Award(Grant) | Apr 8, 2020 | 42,857 |
| HARSH MICHAEL JOHN | Director | Conversion of Exercise of derivative security | Jun 22, 2020 | 69,243 |
| LONGBOARD CAPITAL ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Oct 23, 2018 | 0 |
| MALOBERTI RENAUD BERTRAND | Officer | Sale | Jan 12, 2021 | 1,580 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Virtu Financial LLC | 0.43% | 2,300 | 12.88K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.10% | 549 | 3.07K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.09% | 466 | 2.61K | Sep 29, 2024 |
| Two Sigma Investments, LP | 0.08% | 405 | 2.27K | Sep 29, 2024 |
| HRT Financial LP | 0.07% | 396 | 2.22K | Sep 29, 2024 |
| Jane Street Group, LLC | 0.06% | 320 | 1.79K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.01% | 35 | 195 | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.00% | 23 | 128 | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.00% | 5 | 27 | Oct 30, 2024 |